UC Davis Health and UCLA co-lead $16M study of AI use in breast cancer diagnosis

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

UC Davis Health and UCLA are co-leading a newly funded national clinical trial to evaluate whether AI can help radiologists interpret screening mammograms more accurately. The goal is to improve breast cancer detection and reduce unnecessary callbacks and anxiety for patients.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Jason Chiang and Kyung Sung of the Department of Radiological Sciences at the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center have received a $3.2 million, five-year grant from NCI to develop an artificial intelligence-enhanced imaging platform designed to improve yttrium-90 (Y90) radioembolization planning for patients with liver cancer.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login